Developing a newborn rat model of meningitis without concomitant bacteremia by intraventricular injection of K1 (-) Escherichia coli

Yun Sil Chang¹,²†, So Yoon Ahn¹†, Dong Kyung Sung¹, Young Eun Kim², Se In Sung¹, So Yoon Joo¹, Won Soon Park¹,²*

¹Department of Pediatrics, Samsung Medical Center, Seoul, Korea
²Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea

* Corresponding author
E-mail: ws123.park@samsung.com (WSP)

† These authors contributed equally to this work.

Short title: Newborn meningitis model by intraventricular injection of Escherichia coli
Abstract

Neonatal meningitis caused by *Escherichia coli* results in high mortality and neurological disabilities, and the concomitant systemic bacteremia confounds its mortality and brain injury. This study developed an experimental model of neonatal meningitis without concomitant systemic bacteremia by determining the bacterial inoculum of K1 capsule-negative *E. coli* by intraventricular injection in newborn rats. Meningitis was induced by intraventricular injection of $1 \times 10^2$ (low dose), $5 \times 10^2$ (medium dose), or $1 \times 10^3$ (high dose) colony forming units (CFU) of K1 (-) *E. coli* (EC5ME) in Sprague-Dawley rats at postnatal day 11. Ampicillin was started at postnatal day 12. Blood and cerebrospinal fluid (CSF) cultures were performed at 6 h, 1 day, and 6 days after inoculation. Brain magnetic resonance imaging (MRI) was performed at postnatal days 12 and 17. Survival was monitored, and brain tissues were obtained for histological and biochemical analyses at P12 and P17. Survival was inoculum dose-dependent, with lowest survival in high dose group (20%) compared with medium (80%) or low (70%) dose group. CSF bacterial counts in low and medium dose group were significantly lower than that in high dose group at 6 h, but not at 24 h after inoculation. No bacteria were isolated from the blood throughout the experiment, or from the CSF at postnatal day 17. Brain MRI showed an inoculum dose-dependent increase in the extent of ventriculomegaly, cerebral infarct, extent of brain injury, and inflammatory responses. We developed a newborn rat model of bacterial meningitis without concomitant systemic bacteremia by intraventricular injection of K1 (-) *E.coli*.
Introduction

Despite continuous improvements in antibiotic therapy and intensive care medicine, bacterial meningitis remains a serious disease at any age, and the prognosis is particularly poor in newborn infants, with mortality rates of 20–40% and long-term neurological sequelae, including deafness, blindness, seizures, hydrocephalus, and cognitive impairment in up to 50% of the survivors(1-3). The precise mechanisms by which bacterial infection and the ensuing inflammatory responses in the subarachnoid space during neonatal bacterial meningitis lead to neuronal injury that could result in death or neurological sequelae in survivors are not completely delineated. Therefore, a better understanding of the mechanism of brain damage is necessary to prevent this neuronal injury, and consequently to reduce the mortality and morbidities associated with neonatal bacterial meningitis.

Developing an appropriate animal model that could simulate clinical bacterial meningitis in newborn infants would be essential to determine its pathogenesis, and also to test the efficacy of newly developed adjuvant treatments in addition to the use of antibiotics. Currently, several animal models of neonatal bacterial meningitis, including newborn piglets (4), mice (5-7), rats (8, 9), or rabbits(10) are available, and meningitis was induced by various routes including intraperitoneal (5, 11), intranasal (6), intravenous (5, 10, 12), or intracisternal (7-10, 12) inoculation of bacteria. However, these animal models have certain drawbacks, including small sample size, low infectivity, high mortality, and/or variable extent of brain injury (11). Furthermore, concomitant bacteremia might aggravate the meningitis-induced brain injury (9, 13, 14), thus increasing mortality (8, 9, 15). Therefore, in the present study, we developed a newborn rat model of neonatal bacterial meningitis to mimic the human clinical and neuropathological abnormalities, using 11-day-old newborn
Sprague–Dawley rats with titrated intraventricular inoculation of *Escherichia coli*, the most common gram-negative pathogen of neonatal bacterial meningitis (3). We attempted to determine the bacterial inoculum dose with maximal brain injury and minimal mortality by using K1 capsule-negative *E. coli* to confine the infection to the central nervous system, without concomitant systemic bacteremia (12, 16). We inoculated the bacteria intraventricularly using a stereotaxic frame to simulate the neuropathological progression of clinical neonatal bacterial meningitis, which begins with ventriculitis (17, 18). Brain injury was monitored *in vivo* by brain magnetic resonance imaging (MRI) (19-22).

**MATERIALS AND METHODS**

**Infecting organism**

We used EC5ME, an un-encapsulated mutant of *E. coli* strain possessing the K1 capsular polysaccharide C5 (serotype 018:K1:H7) (a kind gift from Professor Kwang Sik Kim, Johns Hopkins University, MD, USA)(12, 16) to induce only bacterial meningitis, but not secondary bacteremia, in this study. Bacteria were cultured overnight in brain heart infusion broth, diluted in fresh medium, and grown for another 6 h to mid-logarithmic phase. The culture was centrifuged at 5,000 × *g* for 10 min, re-suspended in sterile normal saline to the desired concentration, and used for intraventricular injection. The accuracy of the inoculum size was confirmed by serial dilution, overnight culture on blood agar plates, and then count of colony forming units (CFU).

**Animal model of meningitis**
The experimental protocols described herein including anticipated mortality was reviewed and approved by the Animal Care and Use Committee of Samsung Biomedical Research Institute which provides special training in animal care or handling for research staff. All animal procedures were performed in an AAALAC-accredited specific pathogen-free facility and done in accordance with Institutional and National Institutes of Health Guidelines for Laboratory Animal Care. Fig 1 shows details of the experimental schedule.

The experiment began at P11, and continued through to P17. We assessed and monitored the condition of rat pups on a daily basis regularly. To induce meningitis, newborn Sprague–Dawley rats (Orient Co, Seoul, Korea) were anesthetized using 2% isoflurane in oxygen enriched air, and a total of 10 µl EC5ME inoculum in saline was slowly infused into the left ventricle under stereotactic guidance (Digital Stereotaxic Instrument with Fine Drive, MyNeurolab, St. Louis, MO, USA; coordinates: x = ± 0.5, y = ± 1.0, z = ± 2.5 mm relative to the bregma) at P11. To determine the optimal inoculum dose with minimal mortality and maximal brain injury, we tested three different inoculum doses of \textit{E. coli}: A low inoculum dose of \(1 \times 10^2\) CFU EC5ME (LE), a medium inoculum dose of \(5 \times 10^2\) CFU EC5ME (ME), and a high inoculum dose of \(1 \times 10^3\) CFU EC5ME (HE). For normal control group (NC), equal volume of normal saline was given intraventricularly. After the procedure, the rat pups were allowed to recover and returned to their dams, and there was no mortality associated with the procedure. First, 10 rat pups for each group were allocated to assess the acute pathophysiological changes, and the survivors were sacrificed at 24 h (P12) after bacterial inoculation for histopathological assessment (n = 6, 5, 4 and 3 for the NC, LE, ME and HE groups, respectively) and biochemical analyses (n = 4, 4, 4 and 3 for the NC, LE, ME and HE groups, respectively). We also conducted the time course experiment in 10 animals for each group to determine the survival rate until sacrifice of the survivors at P17 for
histopathological assessment (n = 5, 4, 4 and 2 for the NC, LE, ME and HE groups, respectively) and biochemical analyses (n = 5, 3, 4 and 0 for the NC, LE, ME and HE groups, respectively). Intraperitoneal injection of ampicillin (200 mg/kg/day) was started 6 h after bacterial inoculation, and continued for 3 days until P13. CSF was obtained to determine the bacterial titer at 6 h, 24 h, and 6 days (P17) after bacterial inoculation. Brain MRI was performed at P12 and P17. All experimental procedures generating pain were performed under the isoflurane inhaled anesthesia to reduce pain. All animals were daily monitored and we assessed mortality. Every cause of death was not associated with experimental procedures and related to disease condition. At P12 and P17, survived animals were euthanized by isoflurane and sacrificed by cervical vertebra dislocation and whole brain tissue and CSF samples were obtained.

Fig 1. Experimental protocol. *E. coli* was injected intracerebroventricularly on P11 at different doses for each group; low dose of $1 \times 10^2$ CFU, a medium dose of $5 \times 10^2$ CFU, and a high dose of $1 \times 10^3$ CFU. Brain MRI was performed before the rats were sacrificed.

**Bacterial quantification**

Bacterial concentrations from each study group were measured in the CSF and blood at 6 h, 24 h, and 6 days after bacterial inoculation for induction of meningitis. Bacteria CFU levels in the CSF and blood were measured at dilutions of $10^{-4}$–$10^{-6}$ plated on brain heart infusion agar after overnight incubation at 37°C.

**In vivo brain MRI assessment**
The brain MRI was performed while the rats were kept in an anesthetized state by the administration of 1.5–2% isoflurane in oxygen-enriched air using a facemask. All MRI examinations were performed using a 7.0-tesla MRI System (Bruker-Biospin, Fällanden, Switzerland) prepared with a 20-cm gradient set capable of providing a rising time of 400 mTm-1. The MR images were acquired with 1.0-mm slice thickness, and a total of 12 slices were acquired. Brain MRI was performed at P12 (n = 10, 9, 8 and 6 in the NC, LE, ME and HE groups, respectively) and at P17 (n = 11, 7, 8 and 2 in the NC, LE, ME and HE groups, respectively). After the MRI exams, the rat pups were allowed to recover and were returned to their dams.

**Measurement of the extent of brain injury by MRI**

All MR images were analyzed using Image J software (National Institutes of Health). The lesion was well identified by the hyperintense areas in DWI at P12 and by the hyperintense areas in T2-weighted imaging at P17. The ratio of the infarcted region in the cortex to the whole brain volume was calculated as a parameter of brain injury. The ventriculomegaly volume ratio was also calculated for each pup.

**Tissue preparation**

Brain tissue preparation procedures were performed in the surviving animals until P12 (n = 10, 9, 8 and 6 in the NC, LE, ME and HE groups, respectively) and P17 (n = 10, 7, 8 and 2 in the NC, LE, ME and HE groups, respectively). The animals were anesthetized with sodium pentobarbital (100 mg/kg), and their brains were isolated after thoracotomy and transcardiac perfusion with ice-cold 4% paraformaldehyde in 0.1 mol/l phosphate-buffered saline (PBS). The brains were carefully removed from the animals and fixed overnight with 4%
formaldehyde solution at room temperature. The brains were embedded in paraffin, and
coronal serial sections (4-μm thick) were taken from the paraffin blocks for morphometric
analyses at the level of the medial septum area (+0.95 mm to −0.11/bregma) and the
hippocampal area (−2.85 to −3.70 mm). The sections were stained with hematoxylin and
eosin to assess the extent of neuronal damage.

**TUNEL Assay**

Cell death in the hippocampal region was assessed using the immunofluorescent terminal
deoxynucleotidyltransferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)
technique (kit G3250, Promega, Madison, USA). The slides were mounted with Vectashield
mounting solution with 4′, 6′-diamidino-2-phenylindole dihydrochloride hydrate (DAPI; H-
1200; Vector) and visualized by 20× (dentate gyrus) and 5× tiles can confocal microscopy
(Leica, Wetzlar, Germany). A blinded evaluator counted the density of TUNEL-positive
nuclei in whole brain on coronal brain sections. Six coronal sections (+0.95 mm to −0.11
mm/bregma) were counted from each brain.

**Immunohistochemistry**

Immunohistochemistry of gliosis (neuronal specific glial fibrillary acidic protein [GFAP])
and reactive microglia (ED-1) was performed on deparaffinized 4-μm thick brain sections.
The slices were incubated with the primary anti-GFAP antibodies (rabbit polyclonal; Dako,
Glostrup, Denmark, overnight, 4 °C, 1:1,000 in PBS with 1% bovine serum albumin) and the
anti-ED-1 antibodies (mouse polyclonal; Millipore, CA, USA, overnight, 4 °C, 1:500 in PBS
with 1% bovine serum albumin). After three rinses (same buffer), the sections were incubated
with Alexa Fluor 568 (red) conjugated anti-rabbit immunoglobulin (90 min, diluted 1:500; Molecular Probes, Eugene, OR, USA) and Alexa Fluor 568 (red) conjugated anti-mouse immunoglobulin (90 min, diluted 1:500; Molecular Probes, Eugene Oregon) each. After three rinses, the sections were mounted with Vectashield mounting solution containing 4′, 6′-diamidino-2-phenylindole dihydrochloride hydrate and visualized by 20× (dentate gyrus) and 5× tilescan confocal microscopy (Leica). The density of GFAP-positive cells and the number of ED-1-positive cells were determined by a blinded observer in whole tilescan fields of each animal’s brain using ImageJ software.

**Enzyme-linked immunosorbent assay (ELISA)**

IL-1α, IL-1β, IL-6, and TNF-α concentrations in tissue homogenates were measured at P12 and P17 using the Milliplex MAP ELISA Kit according to the manufacturer’s protocol (Millipore, Billerica, MA, USA).

**Statistical analyses**

Statistical analyses were performed using SPSS version 18.0 (IBM, Chicago, IL, USA). Data are expressed as the mean ± standard error of the mean. For continuous variables, statistical comparison between groups was performed using one-way analysis of variance (ANOVA) and Tukey’s post hoc analysis. P < 0.05 was considered statistically significant.

**Results**

**Survival rates and body weight**
Fig 1 shows the details of the experimental schedule. The experiment began at P11 and continued through to P17. To induce meningitis, at P11, three different doses of E. coli were injected into the cerebroventricles of newborn rats; low inoculum dose of $1 \times 10^2$ CFU (colony forming unit) EC5ME (LE), a medium inoculum dose of $5 \times 10^2$ CFU EC5ME (ME), and a high inoculum dose of $1 \times 10^3$ CFU EC5ME (HE). The survival rate after induction of bacterial meningitis was bacterial inoculum dose-dependent, showing the lowest survival rate up to postnatal day (P)17 of 20% for the high inoculum dose (HE), and 70% and 80% for LE and ME doses, respectively (Fig 2A). While survival rate up to P17 in the HE group was significantly lower compared to that in the no inoculum control (NC), the survival rate of the LE and ME groups was not significantly reduced compared with the NC group.

While birth body and brain weight in each study group was not significantly different between the study groups; the body weight gain at P17 in the LE, ME, and HE groups was significantly lower, the brain weight gain in the ME and HE groups was significantly lower, and the brain/body weight ratio in the ME and HE groups was significantly higher compared with the those in the NC group. The least body and brain weight gain, and the highest brain/body ratio, were observed in the HE group compared with those in the LE and ME groups (Fig 2B-D).

**Fig 2. Survival rates.** (A) Survival rates in each group were determined using Kaplan–Meier analysis followed by a log-rank test. LE, low dose E. coli group; ME, medium dose E. coli group; HE, high dose E. coli group. (B) Brain weight and (C) body weight were measured at P17 in each group (n=11, 7, 9 and 2 in NC, LE, ME, and HE, respectively). Both weights decreased significantly depending on the E. coli dose. (D) The ratio of brain weight: body weight significantly increased in the HE group compared with the other groups others. Data
are presented as the mean ± standard error of the mean (SEM). * P < 0.05 compared with the NC group, # P < 0.05 compared with the LE group, $ P < 0.05 compared with the ME group.

**Bacterial counts**

To evaluate the bacterial burdens, the CFU were counted in the cerebrospinal fluid (CSF) and blood from each study groups at 6 h (P11), 24 h (P12), and 6 days (P17) after induction of meningitis. While no bacterial growth in the blood was detected in all study groups throughout the experiment, the bacterial counts in the CSF at 6 h after the induction of meningitis in both the LE and ME were significantly lower compare with that in the HE. Thereafter, the bacterial counts in the CSF of all study groups increased significantly compared with that at 6 h, and there were no significant inter-group differences at 24 h after the induction of meningitis (Fig 3). No bacterial growth in the CSF was detected all study groups at 6 days after the induction of meningitis.

**Fig 3. Bacterial counts in the CSF.** Bacterial counts in the CSF obtained at 6 and 24 h after bacterial inoculation and before initiation of antibiotic treatment. LE, low dose E. coli group; ME, medium dose E. coli group; HE, high dose E. coli group. Data are presented as the mean ± SEM. * P < 0.05 compared with the NC group, # P < 0.05 compared to LE, $ P < 0.05 compared to ME.

**Brain MRI**

To assess the extent of meningitis-induced brain infarction and hydrocephalus, *in vivo* brain MRI scans were taken. The degree of the brain infarct in the ipsilateral cortex and the dilatation of the ventricle to whole brain as evidenced by the hyperintense areas in the
diffusion-weighted MRI performed at P12 and by T2-weighted MRI performed at P17 were measured.

The brain infarct volume ratios at P12 and P17 were bacterial inoculum dose-dependently increased, showing the highest ratio in the HE group, and a seemingly increased ratio in the ME group compared with that in the LE group that did not reach statistical significance (Fig 4). The ventriculomegaly volume ratios at P12 were bacterial inoculum dose-dependently increased, showing the highest increase in the HE group compared with that in the LE and ME groups. In addition, although the absolute extent of ventriculomegaly was significantly reduced compared with P12, the ventriculomegaly volume ratios at P17 were also bacterial inoculum dose-dependently increased, showing the highest increase in the HE group compared with that in the LE and ME groups (Fig 4).

**Fig 4. Evolution of brain injury at P12 and P17.** (A) Representative brain MRIs of the NE (no *E. coli* control) (left column), LE (middle left column), ME (middle right column), and HE (right column) groups from the medial septal area on day 1 and day 6 after meningitis (P12 and P17). (B) The intact volume of the cortex area to whole brain ratio and (C) the ventriculomegaly volume ratio were measured by MRI at P12 and P17. LE, low dose *E. coli* group; ME, medium dose *E. coli* group; HE, high dose *E. coli* group. Data are presented as the mean ± SEM. * P < 0.05 compared with the NC group, # P < 0.05 compared with the LE group, $ P < 0.05 compared with the ME group.

**TUNEL staining and immunohistochemistry**

To assess the extent of bacterial meningitis-induced cell death, and reactivate gliosis and microglia in the brain, the number of terminal deoxynucleotidyltransferase-mediated
deoxyuridine triphosphate nick-end labeling (TUNEL)- and ED-1 (Ectodysplasin A) positive cells, and the density of glial fibrillary acidic protein (GFAP)-positive cells in the hippocampus were estimated at 24 h after induction of meningitis (P12). The number of TUNEL- and ED-1 positive cells, and the intensity of GFAP-positive cells in the hippocampus at P12 were bacterial inoculum dose-dependently increased compared with the NC group, showing the highest increase in the HE group. The increased number of TUNEL positive cells and the intensity of GFAP positive cells in the ME group were significantly higher compared with those in the LE group (Fig 5).

**Fig 5. Immunostaining in the hippocampus region.** Representative photomicrographs of (A) TUNEL, (C) GFAP intensity, and (E) ED-1 positive cells in the brain of P12 rats in each group. TUNEL intensity was labeled with FITC (green); GFAP and ED-1 positive cells were labeled with TRITC (red). The cell nuclei were labeled with DAPI (blue) (Scale bar = 25 μm). The average intensity of observed (B) TUNEL and (D) GFAP, and the average number of (F) ED-1 positive cells per high-power field (HPF) in each group are also represented. LE, low dose *E. coli* group; ME, medium dose *E. coli* group; HE, high dose *E. coli* group. Data are presented as the mean ± SEM. * P < 0.05 compared with the NC group, # P < 0.05 compared with the LE group, $ P < 0.05$ compared with the ME group.

**Inflammatory Cytokines in Brain**

Levels of inflammatory cytokines, such as interleukin (IL)-1α, IL-1β, IL-6, and tumor necrosis factor alpha (TNF-α) measured in the periventricular brain tissue homogenates at P12 revealed bacterial inoculum dose-dependent increase, showing the highest increase in the HE group. The inflammatory cytokine levels in the ME group were significantly higher.
compared with those in the LE group (Fig 6). Although the brain homogenates of the HE group were not available for measurements because of their high mortality at P17, and the absolute levels of the inflammatory cytokines were significantly reduced compared with P12, the inflammatory cytokines were bacterial inoculum dose-dependently increased, showing significantly higher levels in the ME group compared with those in the LE group.

**Figure 6. Inflammatory cytokines of brain.** Interleukin [IL]-1α, IL-1β, IL-6, and tumor necrosis factor [TNF]-α concentrations in brain tissue homogenates at (A) P12 and (B) P17, were measured using ELISA in each group. LE, low dose *E. coli* group; ME, medium dose *E. coli* group; HE, high dose *E. coli* group. Data are presented as the mean ± SEM. * P < 0.05 compared with the NC group, # P < 0.05 compared with the LE group, $ P < 0.05 compared with the ME group.

**Discussion**

Despite recent improvements in neonatal intensive care medicine and development of highly active new antibiotics, neonatal bacterial meningitis remains a serious disease with high mortality and neurological morbidities in survivors(1, 3). Currently, few effective adjuvant therapies are available to improve the prognosis of this intractable and devastating neonatal disorder. Therefore, developing an appropriate animal model to simulate clinical bacterial meningitis in newborn infants is an essential first step to determine its pathophysiological mechanisms, and to test the therapeutic efficacy of any potential new treatments. However, the limitations of currently available experimental models of meningitis lie in the great variability between the species, the inoculation methods, and the age of the animal models (11). In this study, we used P11 rats as an animal model of neonatal
meningitis because the rat brain at P11 is comparable in terms of maturation to the human
brain at birth (23). The larger size of rat pups compared with mice enables easier surgical
manipulation at an earlier age, and a larger amount of brain tissues obtained at harvest.
Furthermore, our already established newborn rat model of severe Intraventricular
hemorrhage (20-22), middle cerebral arterial occlusion (24), and hypoxic ischemic
encephalopathy (25) with in vivo brain MRI and histopathological analyses to study the
pathophysiological mechanisms and therapeutic efficacy could be easily extrapolated to
develop a newborn rat model of meningitis in this study. Overall, the findings of the present
study suggested that the newborn rat pup model is suitable and appropriate to research the
pathogenesis of neonatal bacterial meningitis and to test the efficacy new treatments.

In this study, E. coli was used to induce meningitis, because it is the most frequent
gram-negative pathogen of neonatal bacterial meningitis (3). Although brain injury primarily
results from local meningeal infection, concomitant systemic bacteremia might aggravate the
meningitis-induced disease severity, brain injury, and mortality (9, 13-15). This discordance
between disease severity and brain injury means that a poorer outcome does not necessarily
lead to increased brain injury (15, 19). In addition, neuroprotection might not be associated
with improved clinical status (26). Therefore, developing an animal model of neonatal
meningitis that could dissect the role of local meningeal infection and systemic bacteremia is
essential to evaluate the pathophysiological mechanism of brain injury and to test the
therapeutic efficacy of any new treatment approaches to reduce the meningitis-induced
sequelae and to improve outcome and survival. As the K1 capsule is the critical determinant
for developing E. coli meningitis in rats, we used K1(-) E. coli in this study to prevent
secondary systemic bacteremia (12, 16). Although we observed secondary bacterial invasion
from the central nervous system (CNS) into the blood stream once the bacterial concentration
in the CSF reached above $10^5$ CFU in our previous experimental study of *E. coli* meningitis in newborn piglets (27), in the present study, we observed no concomitant secondary bacteremia, despite high bacterial concentrations in the CSF well above $10^5$ CFU. Overall, the use of K1 (-) *E. coli* is suitable to study the pathophysiological consequences of meningitis only and the effects of various therapeutic interventions, without the confounding effects of simultaneous systemic bacteremia.

The neuropathology of neonatal bacterial meningitis begins with choroid plexitis and ventriculitis (18, 28, 29), and progresses to arachnoditis and vasculitis, leading to brain edema, hydrocephalus, infarction, and periventricular leukomalacia (30). In the present study, *K1* (-) *E. coli* was injected intraventricularly to induce meningitis because although it bypasses the natural hematogenous bacterial invasion across the blood brain barrier into the CNS(12, 16), this experimental model is more clinically relevant by simulating the clinical neuropathological progression of neonatal bacterial meningitis beginning with ventriculitis (18, 28, 29).

In the present study, we tested three different doses of K1 (-) *E. coli* (EC5ME) for the induction of meningitis to determine the optimal inoculum dose with minimal mortality and maximal brain injury; $1 \times 10^2$ CFU for the LE group, $5 \times 10^2$ CFU for the ME group, and $1 \times 10^3$ CFUs for the HE group. Survival rates, body and brain weight gain, the extent of inflammatory responses and brain injury correlated significantly with the inoculum dose used to induce meningitis, showing highest mortality, extent of inflammatory responses, and brain injury, and the least body and brain weight gain. We also observed higher inflammatory responses and the least extent of brain injury in the ME and LE groups, respectively. The mortality rate was positively correlated with the inoculum dose and the extent of inflammatory responses and brain injury. As blood culture was negative throughout the
experiment, the inoculum dose-dependent increase in mortality, inflammatory responses, and brain injury solely reflects the virulence of EC5ME meningitis, without the confounding effects of the concomitant systemic bacteremia. Overall, these findings suggest that ME (5 × 10^2 CFU) of EC5ME might be optimal inoculum dose to induce neonatal meningitis.

Because bacterial meningitis induces high mortality in newborn infants, the design of animal study was also driven to target for severe, end-stage models. From an ethics viewpoint, this use contradicts views that death as an endpoint is unacceptable. However, the use of alternative end point can generate scientific concerns. Because minor improvements in mortality rates are regarded as major advances in treatment, indefinite endpoint may skew data. Thus, for the development of neonatal meningitis model with proper mortality, precise mortality rate without premature euthanasia was required. Unfortunately, in meningitis model, replacement of animal model is extremely difficult because in vivo immune response is too complicated to model in in vitro system. For the animal welfare, the development of appropriate model which we aimed in the present study would be essential to reduce animal numbers and may be the most valuable refinement for meningitis study.

In infants with bacterial meningitis, brain MRI scans showed abnormalities including cerebral infarct, subdural empyema, cerebritis, and hydrocephalus(19). Increased brain ventriculomegaly in the acute phase of bacterial meningitis in adults was associated with increased mortality (31). In agreement with the clinical findings(19, 31), an acute inoculum dose-dependent increase in ventriculomegaly and cerebral infarct was observed at 1 day after the induction of meningitis. In addition, although a less absolute extent of ventriculomegaly and a higher extent of cerebral infarct were observed compared with post-inoculation day 1, the inoculum dose-dependent abnormalities persisted at 6 days after the induction of meningitis. Taken together, these findings suggested that brain MRI could be an early
prognostic indicator that would be useful to identify patients requiring further therapeutic 
interventions, and to assess the therapeutic efficacy of any new treatments, both in clinical 
and experimental settings of meningitis (19, 31).

Brain injuries observed in experimental models of neonatal meningitis are unique in 
consistently reproducing both hippocampal damage and cortical necrosis (7-9). Inflammatory 
responses are primarily responsible for the ensuing brain injury in bacterial meningitis (3, 7, 
8, 16). In the present study, the extent of inflammatory responses both at post-inoculation day 
1 and 6, and the increased number of TUNEL, GFAP, and ED-1 positive cells in the 
hippocampus at 1 day after induction of meningitis, were associated with the bacterial 
inoculum dose. Antibiotic treatment was started 24 h after bacterial inoculation, and 
continued for 3 days: no bacteria were isolated, even in the CSF, at 5 days after the induction 
of meningitis. Taken together, these findings suggested that increased inflammatory 
responses, but not increased bacterial proliferation and dissemination, triggered by a higher 
bacterial inoculum, are primarily responsible for the ensuing brain injury.

In summary, we successfully developed a newborn rat model of neonatal bacterial 
meningitis without concomitant systemic bacteremia by intraventricular injection of K1 
capsule-negative E. coli at P11. We also determined that a bacterial inoculum dose of $5 \times 10^2$ 
CFU of EC5ME had the minimum mortality, and maximal inflammatory responses and 
ensuing brain injury. This animal model is more clinically relevant because neonatal 
meningitis begins with ventriculitis (18, 28, 29), and could provide the basis for both 
pathophysiology and intervention studies for neonatal bacterial meningitis not confounded by 
simultaneous systemic bacteremia. Hopefully, our newly developed newborn rat model of 
neonatal meningitis will lead to more detailed knowledge of, and new treatments for, this 
intractable and devastating disorder.
Funding

This work was supported by grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR14C0008) and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2017R1D1A1B03035528, NRF-2017R1A2B2011383).

Author contributions

Yun Sil Chang and So Yoon Ahn contributed equally as co-first authors in conceptualization of the study design and hypothesis, data collection and analysis, manuscript writing and revision. Won Soon Park contributed the study idea, design, and hypothesis, data collection and analysis, critically reviewed and revised the manuscript, and serves as the corresponding author. So Yoon Joo, Dong Kyung Sung, and Young Eun Kim contributed conceptualization of the study design, biochemical analysis and wrote a portion of the manuscript, and critically reviewed and revised the manuscript. All authors listed above have read and approved the manuscript.
References


**Timeline of Progeny Development and Procedures**

- **P11**: E. Coli Intraventricular injection
- **P12**: Brain MRI, Sacrifice
- **P13**: Antibiotics
- **P14**: CSF tap
- **P17**: Brain MRI, Sacrifice

Timeline:
- **6hrs** before P12:
  - CSF tap
- **P13**:
  - Antibiotics
- **P14**:
  - CSF tap
- **P17**:
  - CSF tap